1
|
Ammad Ud Din M, Shahzad M, Ashraf A, Liaqat H, Jaan A, Anwer F. Clinical Research in Chronic Lymphocytic Leukemia in Pakistan; A Systematic Review. Medicina (Kaunas) 2023; 59:1483. [PMID: 37629773 PMCID: PMC10456454 DOI: 10.3390/medicina59081483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/15/2023] [Revised: 08/12/2023] [Accepted: 08/16/2023] [Indexed: 08/27/2023]
Abstract
Background: Significant advances have been made in the treatment of chronic lymphocytic leukemia (CLL) since the turn of the new millennium. However, most clinical trials were done in developed countries where minority ethnicities were underrepresented. Materials and Methods: To gauge the quality of research in CLL being done in Pakistan, we conducted a comprehensive literature search using PubMed, Clinicaltrials.gov, and Google Scholar on 14 January 2022 following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. Results: A total of 16 studies met the inclusion criteria. The most common study design was cross-sectional. Eight studies evaluated the clinicohematological profile of CLL patients and the effect of various cytogenic abnormalities through fluorescence in situ hybridization (FISH) technique on disease progression and prognosis. Five studies discussed the prevalence of abnormalities such as autoimmune cytopenias and other serum chemistry derangements. Only two studies evaluated treatment outcomes, among which one study reported a 2-year overall survival of 65% among patients with 17p deletion. None of the studies had patients on novel targeted agents. No pharmaceutical sponsored or funded clinical trials were found. Conclusions: Our review suggests that although small clinical studies continue to be performed across the country, multiple financial and logistical barriers need to be addressed for larger, more impactful clinical trials to be conducted that will help answer demographic-specific questions and decrease reliance on foreign studies.
Collapse
Affiliation(s)
- Mohammad Ammad Ud Din
- Hematology/ Oncology, Moffitt Cancer Center, University of South Florida, 12902 USF Magnolia Drive, Tampa, FL 33612, USA
- Hematology/ Oncology, University of South Florida, Tampa, FL 33612, USA
| | - Moazzam Shahzad
- Hematology/ Oncology, Moffitt Cancer Center, University of South Florida, 12902 USF Magnolia Drive, Tampa, FL 33612, USA
- Hematology/ Oncology, University of South Florida, Tampa, FL 33612, USA
| | - Aqsa Ashraf
- Internal Medicine, Northwell Health Mather Hospital, Port Jefferson, New York, NY 11777, USA
| | - Hania Liaqat
- Internal Medicine, Rochester General Hospital, Rochester, New York, NY 14621, USA
| | - Ali Jaan
- Internal Medicine, Rochester General Hospital, Rochester, New York, NY 14621, USA
| | - Faiz Anwer
- Hematology/ Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
| |
Collapse
|
2
|
Gong JJ, Yin QS, Li MJ, Ai H, Wang Q, Chen L, Wei XD, Song YP. [Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:750-754. [PMID: 31648477 PMCID: PMC7342441 DOI: 10.3760/cma.j.issn.0253-2727.2019.09.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
目的 总结伊布替尼联合嵌合抗原受体T细胞(CAR-T)治疗TP53基因异常超高危慢性淋巴细胞白血病(CLL)/小细胞淋巴瘤(SLL)的经验,提高对此类疾病的认识。 方法 报告1例伴del(17p)CLL/SLL患者BCL-2抑制剂耐药后,采用伊布替尼联合CAR-T成功治疗并顺利桥接异基因造血干细胞移植(allo-HSCT)的治疗经过,并进行文献复习。 结果 患者为年轻女性,发病初表现为全身浅表淋巴结肿大,淋巴结活检病理确诊为SLL,无del(17p);2年后疾病快速进展为CLL/SLL,伴del(17p),骨髓造血衰竭。采用BCL-2抑制剂维奈托克治疗2个月余肿大淋巴结明显缩小,3个月后疾病快速进展,脾脏增大至肋缘下16 cm,颈部淋巴结增大融合,并出现上腔静脉压迫综合征,考虑维奈托克耐药;遂更换为BTK抑制剂伊布替尼治疗,2个月余疾病达部分缓解(PR),联合靶向CD19的CAR-T治疗,细胞因子释放综合征(CRS)1级,1个月后达骨髓及外周血完全缓解(CR),且微小残留病(MRD)阴性,2个月后桥接allo-HSCT。 结论 TP53基因异常CLL/SLL临床进展快、易耐药、预后差,伊布替尼联合CAR-T治疗可快速达CR。
Collapse
Affiliation(s)
- J J Gong
- Department of Hematology, Henan Cancer Hospital; The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | | | | | | | | | | | | | | |
Collapse
|